瑞科生物-B：中国证监会就公司H股全流通计划出具备案通知书

Core Viewpoint - The company has received a filing notice from the China Securities Regulatory Commission regarding the full circulation of H-shares, allowing for the conversion of unlisted shares into H-shares [1] Group 1 - The company has completed the filing for the conversion of a total of 142 million unlisted shares held by 28 shareholders into H-shares [1] - The filing notice is valid for 12 months starting from January 13, 2026 [1] - The company will apply to the Hong Kong Stock Exchange for the approval of the listing and trading of the relevant H-shares [1]